
Novo's CagriSema Cut Weight About 21% at Two Lower Doses in Phase 3 REDEFINE 9 Trial
Shownotes
Novo Nordisk reported full results from REDEFINE 9, the first Phase 3 weight-management trial of its investigational once-weekly injection CagriSema (a fixed-dose combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide) at two doses below the 2.4 mg/2.4 mg dose used across the rest of the REDEFINE program. The results were announced on November 14, 2026, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology. The 68-week trial randomized 309 adults with obesity, or overweight with at least one obesity-related complication, and without diabetes, at 24 sites in Canada, France, Germany, the UK and the US. Each dose was compared with pooled placebo, and the trial was not powered to compare the two doses with each other. If everyone stayed on treatment, average weight loss was 20.7% with CagriSema 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo; counting everyone regardless of stopping treatment, it was 19.4% and 18.6% versus 4.6%. Most side effects were mild to moderate and gastrointestinal; 2.9% and 4.9% stopped treatment because of adverse events, versus 4.9% on placebo, and no deaths were reported. CagriSema is not approved in the US. Novo filed with the FDA in December 2025 for the 2.4 mg/2.4 mg dose for weight management and expects a decision in the fourth quarter of 2026. The trial was funded by Novo Nordisk.
Sources
- Novo Nordisk press release (Nov 14, 2026), CagriSema demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial: prnewswire.com
- The Lancet Diabetes & Endocrinology (Nov 14, 2026), Wharton S, et al., Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): doi.org (abstract on PubMed)
- ObesityWeek 2026 abstract, Poster-344, REDEFINE 9: Effect of CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in Adults with Overweight or Obesity: planion.events
- ClinicalTrials.gov, NCT06388187 (REDEFINE 9): clinicaltrials.gov
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Alle Folgen von GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News